Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study

Josep Callizo,1 Focke Ziemssen,2 Thomas Bertelmann,3 Nicolas Feltgen,3 Jessica Vögeler,4 Mirja Koch,4 Nicole Eter,5 Sandra Liakopoulos,6 Steffen Schmitz-Valckenberg,7 Georg Spital8 1Department of Ophthalmology, Georg-August University, Goettingen, Germany; 2Center for Ophthalmology, Eberhar...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Callizo J, Ziemssen F, Bertelmann T, Feltgen N, Vögeler J, Koch M, Eter N, Liakopoulos S, Schmitz-Valckenberg S, Spital G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	retinal vein occlusion rvo macular edema ranibizumab anti-vegf real-world Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/56f9bab7499440e6b1d57f3e1562835e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:56f9bab7499440e6b1d57f3e1562835e
record_format	dspace
spelling	oai:doaj.org-article:56f9bab7499440e6b1d57f3e1562835e2021-12-02T09:46:28ZReal-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study1177-5483https://doaj.org/article/56f9bab7499440e6b1d57f3e1562835e2019-11-01T00:00:00Zhttps://www.dovepress.com/real-world-data-ranibizumab-treatment-for-retinal-vein-occlusion-in-th-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Josep Callizo,1 Focke Ziemssen,2 Thomas Bertelmann,3 Nicolas Feltgen,3 Jessica Vögeler,4 Mirja Koch,4 Nicole Eter,5 Sandra Liakopoulos,6 Steffen Schmitz-Valckenberg,7 Georg Spital8 1Department of Ophthalmology, Georg-August University, Goettingen, Germany; 2Center for Ophthalmology, Eberhard Karl University of Tuebingen, Tuebingen, Germany; 3Georg-August-University Goettingen, University Eye Hospital, Goettingen, Germany; 4Novartis Pharma GmbH, Clinical Research, Nuremberg, Germany; 5Department of Ophthalmology, University of Muenster Medical Center, Muenster, Germany; 6Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany; 7Department of Ophthalmology, University of Bonn, Bonn, Germany; 8Augenzentrum Am St. Franziskus Hospital, Muenster, GermanyCorrespondence: Josep CallizoDepartment of Ophthalmology, Georg-August University, Robert-Koch-Str. 40, Goettingen 37075, GermanyTel +495513966776Fax +495513966787Email josep.callizo@med.uni-goettingen.dePurpose: The non-interventional OCEAN study (NCT02194803) evaluated frequency and monitoring of ranibizumab injections for retinal vein occlusion (RVO) in routine practice in Germany.Methods: RVO patients (including branch and central RVO (BRVO/CRVO)) receiving ranibizumab were included. Best-corrected visual acuity (BCVA) testing, imaging and treatment were performed at the investigators’ discretion and documented over 24 months.Results: Overall, 744 RVO patients (27% BRVO, 16% CRVO, remaining unspecified RVO) were included. For 74% of patients, data were available for the 12-month visit and for 56% for the 24-month visit. Mean baseline BCVA was 52.0 Early Treatment for Diabetic Retinopathy Study (ETDRS) letters (BRVO: 55.9, CRVO: 43.9). BCVA improved rapidly within the first 3 months, reaching 64.3 letters at 12 months and 64.7 at 24 months. CRVO patients showed less improvement than those with BRVO. Patients received a median of 4 (5) injections over 12 (24) months, with 100% of patients receiving injections at baseline, 70% at Month 1 and 81% at Month 2. Overall, 40% of patients demonstrated a ≥15 letter increase within the first 3 months (42% BRVO, 46% CRVO). Patients with low initial BCVA (<50 letters) showed greater improvement than patients with higher baseline BCVA. Due to considerable loss to follow-up, the number of injections and optical coherence tomography (OCT) examinations were not associated with the change in BCVA.Conclusion: Patients with RVO in routine practice in Germany received fewer injections and fewer OCT examinations than in clinical trials. CRVO patients showed less and later improvement compared to BRVO patients.Keywords: retinal vein occlusion, RVO, macular edema, ranibizumab, anti-VEGF, real-worldCallizo JZiemssen FBertelmann TFeltgen NVögeler JKoch MEter NLiakopoulos SSchmitz-Valckenberg SSpital GDove Medical Pressarticleretinal vein occlusionrvomacular edemaranibizumabanti-vegfreal-worldOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 2167-2179 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	retinal vein occlusion rvo macular edema ranibizumab anti-vegf real-world Ophthalmology RE1-994
spellingShingle	retinal vein occlusion rvo macular edema ranibizumab anti-vegf real-world Ophthalmology RE1-994 Callizo J Ziemssen F Bertelmann T Feltgen N Vögeler J Koch M Eter N Liakopoulos S Schmitz-Valckenberg S Spital G Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study
description	Josep Callizo,1 Focke Ziemssen,2 Thomas Bertelmann,3 Nicolas Feltgen,3 Jessica Vögeler,4 Mirja Koch,4 Nicole Eter,5 Sandra Liakopoulos,6 Steffen Schmitz-Valckenberg,7 Georg Spital8 1Department of Ophthalmology, Georg-August University, Goettingen, Germany; 2Center for Ophthalmology, Eberhard Karl University of Tuebingen, Tuebingen, Germany; 3Georg-August-University Goettingen, University Eye Hospital, Goettingen, Germany; 4Novartis Pharma GmbH, Clinical Research, Nuremberg, Germany; 5Department of Ophthalmology, University of Muenster Medical Center, Muenster, Germany; 6Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany; 7Department of Ophthalmology, University of Bonn, Bonn, Germany; 8Augenzentrum Am St. Franziskus Hospital, Muenster, GermanyCorrespondence: Josep CallizoDepartment of Ophthalmology, Georg-August University, Robert-Koch-Str. 40, Goettingen 37075, GermanyTel +495513966776Fax +495513966787Email josep.callizo@med.uni-goettingen.dePurpose: The non-interventional OCEAN study (NCT02194803) evaluated frequency and monitoring of ranibizumab injections for retinal vein occlusion (RVO) in routine practice in Germany.Methods: RVO patients (including branch and central RVO (BRVO/CRVO)) receiving ranibizumab were included. Best-corrected visual acuity (BCVA) testing, imaging and treatment were performed at the investigators’ discretion and documented over 24 months.Results: Overall, 744 RVO patients (27% BRVO, 16% CRVO, remaining unspecified RVO) were included. For 74% of patients, data were available for the 12-month visit and for 56% for the 24-month visit. Mean baseline BCVA was 52.0 Early Treatment for Diabetic Retinopathy Study (ETDRS) letters (BRVO: 55.9, CRVO: 43.9). BCVA improved rapidly within the first 3 months, reaching 64.3 letters at 12 months and 64.7 at 24 months. CRVO patients showed less improvement than those with BRVO. Patients received a median of 4 (5) injections over 12 (24) months, with 100% of patients receiving injections at baseline, 70% at Month 1 and 81% at Month 2. Overall, 40% of patients demonstrated a ≥15 letter increase within the first 3 months (42% BRVO, 46% CRVO). Patients with low initial BCVA (<50 letters) showed greater improvement than patients with higher baseline BCVA. Due to considerable loss to follow-up, the number of injections and optical coherence tomography (OCT) examinations were not associated with the change in BCVA.Conclusion: Patients with RVO in routine practice in Germany received fewer injections and fewer OCT examinations than in clinical trials. CRVO patients showed less and later improvement compared to BRVO patients.Keywords: retinal vein occlusion, RVO, macular edema, ranibizumab, anti-VEGF, real-world
format	article
author	Callizo J Ziemssen F Bertelmann T Feltgen N Vögeler J Koch M Eter N Liakopoulos S Schmitz-Valckenberg S Spital G
author_facet	Callizo J Ziemssen F Bertelmann T Feltgen N Vögeler J Koch M Eter N Liakopoulos S Schmitz-Valckenberg S Spital G
author_sort	Callizo J
title	Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study
title_short	Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study
title_full	Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study
title_fullStr	Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study
title_full_unstemmed	Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study
title_sort	real-world data: ranibizumab treatment for retinal vein occlusion in the ocean study
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/56f9bab7499440e6b1d57f3e1562835e
work_keys_str_mv	AT callizoj realworlddataranibizumabtreatmentforretinalveinocclusionintheoceanstudy AT ziemssenf realworlddataranibizumabtreatmentforretinalveinocclusionintheoceanstudy AT bertelmannt realworlddataranibizumabtreatmentforretinalveinocclusionintheoceanstudy AT feltgenn realworlddataranibizumabtreatmentforretinalveinocclusionintheoceanstudy AT vogelerj realworlddataranibizumabtreatmentforretinalveinocclusionintheoceanstudy AT kochm realworlddataranibizumabtreatmentforretinalveinocclusionintheoceanstudy AT etern realworlddataranibizumabtreatmentforretinalveinocclusionintheoceanstudy AT liakopouloss realworlddataranibizumabtreatmentforretinalveinocclusionintheoceanstudy AT schmitzvalckenbergs realworlddataranibizumabtreatmentforretinalveinocclusionintheoceanstudy AT spitalg realworlddataranibizumabtreatmentforretinalveinocclusionintheoceanstudy
_version_	1718398005053227008

Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study

Ejemplares similares